Ovid Therapeutics Inc. (OVID) Misses Q3 EPS by 2c

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q3 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $227.17 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy
• RBC Capital Upgrades CAE Inc. (CAE:CN) (CAE) to Outperform
• Nomura/Instinet Downgrades Indraprastha Gas Ltd. (IGL:IN) to Neutral